Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 47Endocrine 3Tumor-Agnostic 2NET 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Neuroendocrine 2Neuroendocrine Tumors 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × IFL protocol × Endocrine × Clear all
NCT02820857 2025-09-03

BEVANEC

Hospices Civils de Lyon

Phase 2 Completed
153 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Biotheus Inc.

Phase 2 Recruiting
60 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03168607 2017-06-01

Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

Peking University

Phase 2 Unknown
45 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡